{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:58:01Z","timestamp":1793383081022,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To present an overview of emerging pharmacological strategies for the prevention and treatment of proliferative vitreoretinopathy (PVR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review critically examines recent experimental and clinical evidence on pharmacological agents targeting key pathogenic mechanisms of PVR, including epithelial\u2013mesenchymal transition, profibrotic cytokine signaling (TGF-\u03b2, PDGF, VEGF), and inflammation-driven tissue remodeling. Investigated compounds include clinically tested substances such as daunorubicin, 5-fluorouracil, corticosteroids, anti-VEGF agents, methotrexate, isotretinoin, decorin and infliximab, as well as newer experimental approaches including Topotecan, Melphalan, ROCK-Inhibitors and gene-regulated therapies. Mechanistic insights into receptor crosstalk, intracellular signaling cascades, and cell survival pathways are integrated with findings from preclinical models and clinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Several agents have shown anti-proliferative and anti-inflammatory effects in vitro and in vivo, with methotrexate and infliximab emerging as particularly promising candidates. However, clinical data remain heterogeneous, and no pharmacological agent has yet received regulatory approval for PVR treatment. Risk stratification based on preoperative PVR, vitreous hemorrhage, or ocular trauma may help optimize patient selection in future trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacological modulation of PVR is conceptually well supported by preclinical data, but clinical translation remains limited. Well-designed randomized trials in clearly defined high-risk populations are needed to validate efficacy, determine optimal treatment windows, and develop standardized protocols for both prophylaxis and therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-026-03963-6","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:00:55Z","timestamp":1769835655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug strategies for the treatment and prevention of proliferative vitreoretinopathy: an overview of innovative treatment concepts"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8618-556X","authenticated-orcid":false,"given":"Adrian Konstantin","family":"Luyken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Junge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Armin","family":"Fuchsluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Schaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"12","key":"3963_CR1","first-page":"1771","volume":"29","author":"R Machemer","year":"1988","unstructured":"Machemer R (1988) Proliferative vitreoretinopathy (PVR): a personal account of its pathogenesis and treatment. Proctor lecture Invest Ophthalmol Vis Sci. 29(12):1771\u20131783","journal-title":"Proctor lecture Invest Ophthalmol Vis Sci."},{"key":"3963_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.preteyeres.2013.12.006","volume":"40","author":"S Pennock","year":"2014","unstructured":"Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A (2014) Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res 40:16\u201334","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"3963_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0002-9394(14)76695-4","volume":"112","author":"R Machemer","year":"1991","unstructured":"Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM (1991) An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 112(2):159\u2013165","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"3963_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1350-9462(01)00023-4","volume":"21","author":"JC Pastor","year":"2002","unstructured":"Pastor JC, de la R\u00faa ER, Mart\u00edn F (2002) Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res 21(1):127\u2013144","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"3963_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00347-020-01173-8","volume":"118","author":"F Schaub","year":"2021","unstructured":"Schaub F, Abdullatif AM, Fauser S (2021) Proliferative Vitreoretinopathieprophylaxe. Ophthalmol 118(1):3\u20139","journal-title":"Ophthalmol"},{"key":"3963_CR6","unstructured":"Hunter G, Maclean N, Watson S, Colyer M, Leong J, Agrawal R, 2025 Non-surgical interventions for proliferative vitreoretinopathy\u2014a systematic review Eye 1\u201319."},{"issue":"10","key":"3963_CR7","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.1074\/jbc.M808426200","volume":"284","author":"H Lei","year":"2009","unstructured":"Lei H, Kazlauskas A (2009) Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species\/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J Biol Chem 284(10):6329\u20136336","journal-title":"J Biol Chem"},{"issue":"110","key":"3963_CR8","first-page":"207","volume":"20","author":"S Yang","year":"2015","unstructured":"Yang S, Li H, Li M, Wang F (2015) Mechanisms of epithelial-mesenchymal transition in proliferative vitreoretinopathy. Discov Med 20(110):207\u2013217","journal-title":"Discov Med"},{"issue":"1","key":"3963_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.exer.2005.12.007","volume":"83","author":"MA Gamulescu","year":"2006","unstructured":"Gamulescu MA, Chen Y, He S, Spee C, Jin M, Ryan SJ (2006) Transforming growth factor beta2-induced myofibroblastic differentiation of human retinal pigment epithelial cells: regulation by extracellular matrix proteins and hepatocyte growth factor. Exp Eye Res 83(1):212\u2013222","journal-title":"Exp Eye Res"},{"key":"3963_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fcell.2020.00501","volume":"8","author":"M Zhou","year":"2020","unstructured":"Zhou M, Geathers JS, Grillo SL, Weber SR, Wang W, Zhao Y (2020) Role of epithelial-mesenchymal transition in retinal pigment epithelium dysfunction. Front Cell Dev Biol 8:501","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"3963_CR11","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1128\/MCB.06668-11","volume":"32","author":"S Pennock","year":"2012","unstructured":"Pennock S, Kazlauskas A (2012) Vascular endothelial growth factor a competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Mol Cell Biol Mai 32(10):1955\u20131966","journal-title":"Mol Cell Biol Mai"},{"issue":"9","key":"3963_CR12","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1128\/MCB.01321-10","volume":"31","author":"H Lei","year":"2011","unstructured":"Lei H, Velez G, Kazlauskas A (2011) Pathological signaling via platelet-derived growth factor receptor alpha involves chronic activation of Akt and suppression of p53. Mol Cell Biol 31(9):1788\u20131799","journal-title":"Mol Cell Biol"},{"issue":"1","key":"3963_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/02713683.2024.2388686","volume":"50","author":"X Chen","year":"2025","unstructured":"Chen X, Yue Y, Wang H, Liu L (2025) ASPP2 upregulation as a novel approach to TGF-\u03b22-induced proliferative vitreoretinopathy in vivo and in vitro. Curr Eye Res 50(1):74\u201381","journal-title":"Curr Eye Res"},{"issue":"3","key":"3963_CR14","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3390\/ijms26031025","volume":"26","author":"N Harju","year":"2025","unstructured":"Harju N, Kauppinen A, Loukovaara S (2025) Fibrotic changes in rhegmatogenous retinal detachment. Int J Mol Sci 26(3):1025","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3963_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/17469899.2022.2100764","volume":"17","author":"CH Jones","year":"2022","unstructured":"Jones CH, Gui W, Schumann RG, Boneva SK, Lange CAK, Van Overdam KA (2022) Hyalocytes in proliferative vitreo-retinal diseases. Expert Rev Ophthalmol 17(4):263\u2013280","journal-title":"Expert Rev Ophthalmol"},{"issue":"1","key":"3963_CR16","doi-asserted-by":"publisher","first-page":"16386","DOI":"10.1038\/srep16386","volume":"5","author":"K Ishikawa","year":"2015","unstructured":"Ishikawa K, He S, Terasaki H, Nazari H, Zhang H, Spee C (2015) Resveratrol inhibits epithelial-mesenchymal transition of retinal pigment epithelium and development of proliferative vitreoretinopathy. Sci Rep 5(1):16386","journal-title":"Sci Rep"},{"issue":"2","key":"3963_CR17","doi-asserted-by":"publisher","first-page":"e56819","DOI":"10.1371\/journal.pone.0056819","volume":"8","author":"CM Chan","year":"2013","unstructured":"Chan CM, Chang HH, Wang VC, Huang CL, Hung CF (2013) Inhibitory effects of resveratrol on PDGF-BB-induced retinal pigment epithelial cell migration via PDGFR\u03b2, PI3K\/Akt and MAPK pathways. PLoS ONE 8(2):e56819","journal-title":"PLoS ONE"},{"issue":"9","key":"3963_CR18","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/j.apsb.2021.01.001","volume":"11","author":"J Liu","year":"2021","unstructured":"Liu J, Ren L, Li S, Li W, Zheng X, Yang Y (2021) The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B 11(9):2783\u20132797","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"3963_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00417-007-0743-x","volume":"246","author":"J Sebag","year":"2008","unstructured":"Sebag J (2008) Vitreoschisis. Graefes Arch Clin Exp Ophthalmol 246(3):329\u2013332","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"3963_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/aos.15687","volume":"102","author":"KA Van Overdam","year":"2024","unstructured":"Van Overdam KA, Van Etten PG, Accou GPBM, Wubbels RJ, Van Meurs JC, Verhoekx JSN (2024) Prevalence of vitreoschisis-induced vitreous cortex remnants over the peripheral retinal surface in eyes undergoing vitrectomy for primary rhegmatogenous retinal detachment. Acta Ophthalmol (Copenh) 102(1):99\u2013106","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"9","key":"3963_CR21","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s00417-024-06448-3","volume":"262","author":"C Lange","year":"2024","unstructured":"Lange C, Boneva S, Wieghofer P, Sebag J (2024) Hyalocytes\u2014guardians of the vitreoretinal interface. Graefes Arch Clin Exp Ophthalmol 262(9):2765\u20132784","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"3963_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/iovs.63.5.17","volume":"63","author":"Y Laich","year":"2022","unstructured":"Laich Y, Wolf J, Hajdu RI, Schlecht A, Bucher F, Pauleikhoff L (2022) Single-cell protein and transcriptional characterization of epiretinal membranes from patients with proliferative vitreoretinopathy. Investig Opthalmology Vis Sci 63(5):17","journal-title":"Investig Opthalmology Vis Sci"},{"key":"3963_CR23","doi-asserted-by":"publisher","first-page":"757607","DOI":"10.3389\/fimmu.2021.757607","volume":"12","author":"SK Boneva","year":"2021","unstructured":"Boneva SK, Wolf J, Hajd\u00fa RI, Prinz G, Sali\u00e9 H, Schlecht A (2021) In-Depth molecular characterization of neovascular membranes suggests a role for hyalocyte-to-myofibroblast transdifferentiation in proliferative diabetic retinopathy. Front Immunol 12:757607","journal-title":"Front Immunol"},{"issue":"1","key":"3963_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1350-9462(97)00007-4","volume":"17","author":"H Nagasaki","year":"1998","unstructured":"Nagasaki H, Shinagawa K, Mochizuki M (1998) Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res 17(1):77\u201398","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"3963_CR25","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/bjo.84.5.506","volume":"84","author":"CH Kon","year":"2000","unstructured":"Kon CH, Asaria RHY, Occleston NL, Khaw PT, Aylward GW (2000) Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol 84(5):506\u2013511","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"3963_CR26","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0161-6420(01)00553-X","volume":"108","author":"RHY Asaria","year":"2001","unstructured":"Asaria RHY, Kon CH, Bunce C, Charteris DG, Wong D, Luthert PJ (2001) How to predict proliferative vitreoretinopathy: a prospective study1. Ophthalmology 108(7):1184\u20131186","journal-title":"Ophthalmology"},{"issue":"10","key":"3963_CR27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.ophtha.2022.05.024","volume":"129","author":"F Schaub","year":"2022","unstructured":"Schaub F, Schiller P, Hoerster R, Kraus D, Holz FG, Guthoff R (2022) Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial. Ophthalmology 129(10):1129\u20131141","journal-title":"Ophthalmology"},{"issue":"12","key":"3963_CR28","first-page":"1079","volume":"115","author":"F Schaub","year":"2018","unstructured":"Schaub F, Fauser S, Kirchhof B, Witte A, H\u00f6rster R (2018) Laser flare photometry for identification of high-risk patients for proliferative vitreoretinopathy. Ophthalmol Z Dtsch Ophthalmol Ges 115(12):1079\u20131083","journal-title":"Ophthalmol Z Dtsch Ophthalmol Ges"},{"issue":"10","key":"3963_CR29","doi-asserted-by":"publisher","first-page":"e0292698","DOI":"10.1371\/journal.pone.0292698","volume":"18","author":"J Xiang","year":"2023","unstructured":"Xiang J, Fan J, Wang J (2023) Risk factors for proliferative vitreoretinopathy after retinal detachment surgery: a systematic review and meta-analysis. PLoS ONE 18(10):e0292698","journal-title":"PLoS ONE"},{"issue":"13","key":"3963_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1167\/iovs.65.13.56","volume":"65","author":"S Wohlfart","year":"2024","unstructured":"Wohlfart S, Herth J, B\u00f6hmann MB, Pander G, Herbster L, Mier W (2024) Exposure to silicone oil endotamponades induces VEGF antibody aggregation and loss of functionality. Invest Ophthalmol Vis Sci 65(13):56","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3963_CR31","doi-asserted-by":"publisher","first-page":"1029584","DOI":"10.3389\/fphar.2022.1029584","volume":"13","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Liu Y, Gou Y, Xu H, Gao Y, Liu Y (2022) Efficacy and safety of the dexamethasone implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema: A systematic review and meta-analysis. Front Pharmacol 13:1029584","journal-title":"Front Pharmacol"},{"issue":"1","key":"3963_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40942-018-0127-x","volume":"4","author":"EO Flores-Villalobos","year":"2018","unstructured":"Flores-Villalobos EO, Ram\u00edrez-Estudillo JA, Robles-Contreras A, Oliva-Ram\u00edrez JL (2018) Dexamethasone implant in silicone oil: in vitro behavior. Int J Retina Vitr 4(1):24","journal-title":"Int J Retina Vitr"},{"issue":"7","key":"3963_CR33","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/pharmaceutics14071364","volume":"14","author":"M Hammer","year":"2022","unstructured":"Hammer M, Schickhardt SK, Merz PR, Khoramnia R, Scheuerle AF, Mier W (2022) Intravitreal application: physicochemical properties of drugs dissolved in silicone oils of different density in comparison to the porcine vitreous body. Pharmaceutics 14(7):1364","journal-title":"Pharmaceutics"},{"issue":"1","key":"3963_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/archopht.116.1.69","volume":"116","author":"CS Yang","year":"1998","unstructured":"Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H (1998) An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 116(1):69\u201377","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"3963_CR35","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0002-9394(14)76037-4","volume":"99","author":"DB Chandler","year":"1985","unstructured":"Chandler DB, Rozakis G, de Juan E, Machemer R (1985) The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol 99(6):686\u2013690","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"3963_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF02150144","volume":"225","author":"DB Chandler","year":"1987","unstructured":"Chandler DB, Hida T, Sheta S, Proia AD, Machemer R (1987) Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefes Arch Clin Exp Ophthalmol 225(4):259\u2013265","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"3963_CR37","first-page":"757","volume":"124","author":"PJ Banerjee","year":"2017","unstructured":"Banerjee PJ, Quartilho A, Bunce C, Xing W, Zvobgo TM, Harris N (2017) Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective. Randomiz Controll Clinic Trial Ophthalmol 124(6):757\u2013767","journal-title":"Randomiz Controll Clinic Trial Ophthalmol"},{"issue":"5","key":"3963_CR38","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/S0008-4182(05)80052-3","volume":"40","author":"WM Munir","year":"2005","unstructured":"Munir WM, Pulido JS, Sharma MC, Buerk BM (2005) Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol J Can Ophtalmol 40(5):598\u2013604","journal-title":"Can J Ophthalmol J Can Ophtalmol"},{"issue":"5","key":"3963_CR39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3928\/15428877-20070901-02","volume":"38","author":"RA Cheema","year":"2007","unstructured":"Cheema RA, Peyman GA, Fang T, Jones A, Lukaris AD, Lim K (2007) Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging Retina 38(5):365\u2013370","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"7","key":"3963_CR40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00417-011-1919-y","volume":"250","author":"F Koerner","year":"2012","unstructured":"Koerner F, Koerner-Stiefbold U, Garweg JG (2012) Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial. Graefes Arch Clin Exp Ophthalmol 250(7):981\u2013987","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"3963_CR41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1167\/iovs.10-5285","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD (2011) Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52(1):80\u201386","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3\u20134","key":"3963_CR42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000371901","volume":"233","author":"HK Kuo","year":"2015","unstructured":"Kuo HK, Chen YH, Wu PC, Kuo YH (2015) The effects of Ozurdex\u00ae (dexamethasone intravitreal implant) on experimental proliferative vitreoretinopathy. Ophthalmologica 233(3\u20134):198\u2013203","journal-title":"Ophthalmologica"},{"issue":"8","key":"3963_CR43","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/bjo-2023-324318","volume":"108","author":"H Guo","year":"2024","unstructured":"Guo H, Yu J, He T, Chen S, Sun Z, Zhang J (2024) Early use of intravitreal triamcinolone to inhibit traumatic proliferative vitreoretinopathy: a randomised clinical trial. Br J Ophthalmol 108(8):1161\u20131167","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"3963_CR44","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/bjo-2022-322787","volume":"108","author":"EJ Casswell","year":"2024","unstructured":"Casswell EJ, Cro S, Cornelius VR, Banerjee PJ, Zvobgo TM, Tudor Edwards R (2024) Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: the ASCOT study. Br J Ophthalmol 108(3):440\u2013448","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"3963_CR45","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/BF00184858","volume":"234","author":"RG Williams","year":"1996","unstructured":"Williams RG, Chang S, Comaratta MR, Simoni G (1996) Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol 234(8):496\u2013503","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"3963_CR46","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0002-9394(98)00115-9","volume":"126","author":"P Wiedemann","year":"1998","unstructured":"Wiedemann P, Hilgers RD, Bauer P, Heimann K (1998) Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group Am J Ophthalmol 126(4):550\u2013559","journal-title":"Daunomycin Study Group Am J Ophthalmol"},{"issue":"5","key":"3963_CR47","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1046\/j.1442-9071.2002.00554.x","volume":"30","author":"A Kumar","year":"2002","unstructured":"Kumar A, Nainiwal S, Choudhary I, Tewari HK, Verma LK (2002) Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery. Clin Exp Ophthalmol 30(5):348\u2013351","journal-title":"Clin Exp Ophthalmol"},{"issue":"3 Suppl","key":"3963_CR48","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1097\/00006982-199212031-00015","volume":"12","author":"MS Blumenkranz","year":"1992","unstructured":"Blumenkranz MS, Hartzer MK, Iverson D (1992) An overview of potential applications of heparin in vitreoretinal surgery. Retina Phila Pa 12(3 Suppl):S71-74","journal-title":"Retina Phila Pa"},{"issue":"3","key":"3963_CR49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/archopht.1991.01080030107048","volume":"109","author":"DA Iverson","year":"1991","unstructured":"Iverson DA, Katsura H, Hartzer MK, Blumenkranz MS (1991) Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy. Arch Ophthalmol 109(3):405\u2013409","journal-title":"Arch Ophthalmol"},{"key":"3963_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006421.pub3\/full","author":"V Sundaram","year":"2010","unstructured":"Sundaram V, Barsam A, Virgili G (2010) Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database of Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD006421.pub3\/full","journal-title":"Cochrane Database of Syst Rev"},{"issue":"1","key":"3963_CR51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12886-024-03362-4","volume":"24","author":"M Nasr","year":"2024","unstructured":"Nasr M, Abdelhadi A, Bessa A, Ibrahim TM (2024) Efficacy of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) in high-risk pediatric retinal detachment; randomized clinical trial. BMC Ophthalmol 24(1):97","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"3963_CR52","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1006\/exer.1997.0355","volume":"65","author":"J Veloso","year":"1997","unstructured":"Veloso J, Amadeo AS, Kadrmas EF, Larrosa JM, Sandberg MA, Tolentino FI, Refojo MF (1997) 13-cis-retinoic acid in silicone-fluorosilicone copolymer oil in a rabbit model of proliferative vitreoretinopathy. Exp Eye Res 65(3):425\u2013434","journal-title":"Exp Eye Res"},{"issue":"9","key":"3963_CR53","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/bjophthalmol-2018-312839","volume":"103","author":"NJS London","year":"2019","unstructured":"London NJS, Kaiser RS, Khan MA, Alshareef RA, Khuthaila M, Shahlaee A (2019) Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial. Br J Ophthalmol 103(9):1306\u20131313","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"3963_CR54","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ajo.2008.05.002","volume":"146","author":"YC Chang","year":"2008","unstructured":"Chang YC, Hu DN, Wu WC (2008) Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. Am J Ophthalmol 146(3):440\u2013446","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"3963_CR55","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/jop.2022.0078","volume":"39","author":"N Tersi","year":"2023","unstructured":"Tersi N, Kassumeh S, Ohlmann A, Strehle L, Priglinger SG, Hartmann D (2023) Pharmacological therapy of proliferative vitreoretinopathy: systematic in vitro comparison of 36 pharmacological agents. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther 39(2):148\u2013158","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"issue":"7","key":"3963_CR56","doi-asserted-by":"publisher","first-page":"e1070","DOI":"10.1111\/aos.14735","volume":"99","author":"A Schulz","year":"2021","unstructured":"Schulz A, Rickmann A, Julich-Haertel H, Germann A, von Briesen H, Januschowski K (2021) Comparative cytotoxic and antiproliferative profile of methotrexate and fluorouracil on different ocular cells. Acta Ophthalmol (Copenh) 99(7):e1070\u2013e1076","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"10","key":"3963_CR57","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1167\/iovs.16-20912","volume":"58","author":"D Amarnani","year":"2017","unstructured":"Amarnani D, Machuca-Parra AI, Wong LL, Marko CK, Stefater JA, Stryjewski TP (2017) Effect of methotrexate on an in vitro patient-derived model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 58(10):3940\u20133949","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"3963_CR58","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.3.23","volume":"9","author":"R Chaudhary","year":"2020","unstructured":"Chaudhary R, Scott RAH, Wallace G, Berry M, Logan A, Blanch RJ (2020) Inflammatory and fibrogenic factors in proliferative vitreoretinopathy development. Transl Vis Sci Technol 9(3):23","journal-title":"Transl Vis Sci Technol"},{"issue":"2","key":"3963_CR59","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/24741264221135799","volume":"7","author":"MA McAllister","year":"2023","unstructured":"McAllister MA, Moore SM, Bullock B, Christoforidis JB (2023) Intraocular methotrexate for the treatment and prevention of proliferative vitreoretinopathy: a review. J Vitreoretin Dis 7(2):144\u2013153","journal-title":"J Vitreoretin Dis"},{"issue":"4","key":"3963_CR60","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.oret.2024.10.006","volume":"9","author":"T Liu","year":"2025","unstructured":"Liu T, Runner M, Mahmoud TH, Capone A, Drenser KA, Randhawa S (2025) A Modified intravitreal methotrexate protocol for the prevention of proliferative vitreoretinopathy after silicone oil removal. Ophthalmol Retina 9(4):314\u2013321","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"3963_CR61","first-page":"387","volume":"263","author":"RP Rajan","year":"2025","unstructured":"Rajan RP, Babu KN, Arumugam KK, Muraleedharan S, Ramachandran O, Jena S (2025) Intravitreal methotrexate as an adjuvant in vitrectomy in cases of retinal detachment with proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 263(2):387\u2013391","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"10","key":"3963_CR62","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2147\/OPTH.S111893","volume":"19","author":"A Sadaka","year":"2016","unstructured":"Sadaka A, Sisk RA, Osher JM, Toygar O, Duncan MK, Riemann CD (2016) Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol Auckl NZ 19(10):1811\u20131817","journal-title":"Clin Ophthalmol Auckl NZ"},{"issue":"7","key":"3963_CR63","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4103\/0301-4738.109518","volume":"61","author":"EB Ozkan","year":"2013","unstructured":"Ozkan EB, Ozcan AA, Sekeroglu HT, Kuyucu Y, Ozgun H, Polat S (2013) Intravitreal injection of methotrexate in an experimental rabbit model: determination of ultrastructural changes. Indian J Ophthalmol 61(7):329\u2013333","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"3963_CR64","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00417-015-3007-1","volume":"253","author":"S Manna","year":"2015","unstructured":"Manna S, Banerjee RK, Augsburger JJ, Al-Rjoub MF, Donnell A, Correa ZM (2015) Biodegradable chitosan and polylactic acid-based intraocular micro-implant for sustained release of methotrexate into vitreous: analysis of pharmacokinetics and toxicity in rabbit eyes. Graefes Arch Clin Exp Ophthalmol 253(8):1297\u20131305","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"3963_CR65","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/bjo.2007.127928","volume":"92","author":"S Frenkel","year":"2008","unstructured":"Frenkel S, Hendler K, Siegal T, Shalom E, Pe\u2019Er, J. (2008) Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 92(3):383\u2013388","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"3963_CR66","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904\u20131914","journal-title":"Ophthalmology"},{"key":"3963_CR67","doi-asserted-by":"publisher","first-page":"114088","DOI":"10.1016\/j.biopha.2022.114088","volume":"158","author":"SS Arrow","year":"2023","unstructured":"Arrow SS, Felis SC, Hillenmayer A, Strehle LD, Koenig SF, Vounotrypidis E (2023) Inhibition of proliferative vitreoretinopathy by a newly developed methotrexate loaded drug carrier in vitro. Biomed Pharmacother Biomed Pharmacother 158:114088","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"key":"3963_CR68","doi-asserted-by":"crossref","unstructured":"Hammer M, Skrzypczyk L, Wohlfart S, Ackermann BC, Geisweid L, Pohl SW, 2025 Methotrexate-Loaded Liposomal Formulation Enables 6-Week Sustained Intraocular Therapeutic Drug Release in a Porcine Model. Adv Healthc Mater. n\/a(n\/a):e03230.","DOI":"10.1002\/adhm.202503230"},{"issue":"3","key":"3963_CR69","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41433-024-03503-5","volume":"39","author":"VTR Toh","year":"2025","unstructured":"Toh VTR, Gerard G, Tay ZQ, Chen J, Chew GWM, Teoh CS (2025) Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review. Eye 39(3):460\u2013467","journal-title":"Eye"},{"issue":"5","key":"3963_CR70","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.oret.2024.10.023","volume":"9","author":"X Chen","year":"2025","unstructured":"Chen X, Keenan JD, Stewart JM (2025) Association between systemic methotrexate therapy and proliferative vitreoretinopathy. Ophthalmol Retina 9(5):431\u2013436","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"3963_CR71","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/15569527.2019.1701000","volume":"39","author":"F Savur","year":"2020","unstructured":"Savur F, Aydemir O, \u0130lhan N (2020) The effect of infliximab and octreotide on cytokine levels experimental proliferative vitreoretinopathy. Cutan Ocul Toxicol 39(1):61\u201366","journal-title":"Cutan Ocul Toxicol"},{"issue":"11","key":"3963_CR72","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.oret.2024.05.016","volume":"8","author":"AM Younes","year":"2024","unstructured":"Younes AM, Hamza HS, Omar HA, Abdel-Kader AA, Abdelbaki AM, Elnahry AG (2024) Intravitreal infliximab for the treatment of proliferative vitreoretinopathy (FIXER): a\u00a0randomized controlled phase II trial. Ophthalmol Retina 8(11):1044\u20131051","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"3963_CR73","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3928\/01913913-20220727-03","volume":"60","author":"MR Barke","year":"2023","unstructured":"Barke MR, Negretti GS, Shields CL (2023) Melphalan versus topotecan for retinoblastoma vitreous seeds. J Pediatr Ophthalmol Strabismus 60(4):304","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"1","key":"3963_CR74","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1186\/s13063-023-07815-x","volume":"24","author":"M H\u00e9bert","year":"2023","unstructured":"H\u00e9bert M, Bourgault S, Caissie M, Tourville \u00c9, Dirani A (2023) REtinal Detachment outcomes study (REDOS): study protocol for a factorial, randomized controlled trial. Trials 24(1):820","journal-title":"Trials"},{"issue":"3","key":"3963_CR75","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4103\/2008-322X.188390","volume":"11","author":"A Tousi","year":"2016","unstructured":"Tousi A, Hasanpour H, Soheilian M (2016) Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: a randomized pilot study. J Ophthalmic Vis Res 11(3):271\u2013276","journal-title":"J Ophthalmic Vis Res"},{"issue":"5","key":"3963_CR76","first-page":"576","volume":"28","author":"K Ghasemi Falavarjani","year":"2014","unstructured":"Ghasemi Falavarjani K, Hashemi M, Modarres M, Hadavand KA (2014) Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. Eye Lond Engl 28(5):576\u2013580","journal-title":"Eye Lond Engl"},{"issue":"1","key":"3963_CR77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yexmp.2004.07.006","volume":"78","author":"W Huijun","year":"2005","unstructured":"Huijun W, Long C, Zhigang Z, Feng J, Muyi G (2005) Ex vivo transfer of the decorin gene into rat glomerulus via a mesangial cell vector suppressed extracellular matrix accumulation in experimental glomerulonephritis. Exp Mol Pathol 78(1):17\u201324","journal-title":"Exp Mol Pathol"},{"issue":"6","key":"3963_CR78","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/jcb.20776","volume":"98","author":"G Zhang","year":"2006","unstructured":"Zhang G, Ezura Y, Chervoneva I, Robinson PS, Beason DP, Carine ET (2006) Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. J Cell Biochem 98(6):1436\u20131449","journal-title":"J Cell Biochem"},{"issue":"6","key":"3963_CR79","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.matbio.2006.04.004","volume":"25","author":"R Droguett","year":"2006","unstructured":"Droguett R, Cabello-Verrugio C, Riquelme C, Brandan E (2006) Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol J Int Soc Matrix Biol 25(6):332\u2013341","journal-title":"Matrix Biol J Int Soc Matrix Biol"},{"issue":"5","key":"3963_CR80","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1161\/01.ATV.21.5.777","volume":"21","author":"JW Fischer","year":"2001","unstructured":"Fischer JW, Kinsella MG, Levkau B, Clowes AW, Wight TN (2001) Retroviral overexpression of decorin differentially affects the response of arterial smooth muscle cells to growth factors. Arterioscler Thromb Vasc Biol 21(5):777\u2013784","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"3963_CR81","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1006\/exnr.1999.7180","volume":"159","author":"A Logan","year":"1999","unstructured":"Logan A, Baird A, Berry M (1999) Decorin attenuates gliotic scar formation in the rat cerebral hemisphere. Exp Neurol 159(2):504\u2013510","journal-title":"Exp Neurol"},{"issue":"11","key":"3963_CR82","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0006-2952(97)00343-2","volume":"54","author":"SN Giri","year":"1997","unstructured":"Giri SN, Hyde DM, Braun RK, Gaarde W, Harper JR, Pierschbacher MD (1997) Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 54(11):1205\u20131216","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"3963_CR83","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nm0496-418","volume":"2","author":"Y Isaka","year":"1996","unstructured":"Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA (1996) Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2(4):418\u2013423","journal-title":"Nat Med"},{"issue":"4","key":"3963_CR84","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/03635465010290040201","volume":"29","author":"K Fukushima","year":"2001","unstructured":"Fukushima K, Badlani N, Usas A, Riano F, Fu F, Huard J (2001) The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med 29(4):394\u2013402","journal-title":"Am J Sports Med"},{"issue":"1","key":"3963_CR85","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1167\/iovs.04-0902","volume":"46","author":"S Grisanti","year":"2005","unstructured":"Grisanti S, Szurman P, Warga M, Kaczmarek R, Ziemssen F, Tatar O (2005) Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study. Invest Ophthalmol Vis Sci 46(1):191\u2013196","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"3963_CR86","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00417-011-1730-9","volume":"249","author":"K Nassar","year":"2011","unstructured":"Nassar K, L\u00fcke J, L\u00fcke M, Kamal M, Abd El-Nabi E, Soliman M (2011) The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 249(11):1649\u20131660","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"12","key":"3963_CR87","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s00417-018-4105-7","volume":"256","author":"AM Abdullatif","year":"2018","unstructured":"Abdullatif AM, Macky TA, Abdullatif MM, Nassar K, Grisanti S, Mortada HA (2018) Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 256(12):2473\u20132481","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"key":"3963_CR88","doi-asserted-by":"publisher","first-page":"8543592","DOI":"10.1155\/2017\/8543592","volume":"2017","author":"M Yamaguchi","year":"2017","unstructured":"Yamaguchi M, Nakao S, Arima M, Wada I, Kaizu Y, Hao F (2017) Rho-Kinase\/ROCK as a potential drug target for vitreoretinal diseases. J Ophthalmol 2017:8543592","journal-title":"J Ophthalmol"},{"key":"3963_CR89","unstructured":"Hsu J A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Study on the Use of Rho-Kinase Inhibitor to Reduce Ore Prevent Proliferative Vitreoretinopathy (PVR) in Eyes With Rhegmatogenous Retinal Detachment (RRD) at High Risk of PVR [Internet]. clinicaltrials.gov; 2024 Juli [zitiert 22. November 2025]. Report No.: NCT05660447. Verf\u00fcgbar unter: https:\/\/clinicaltrials.gov\/study\/NCT05660447"},{"key":"3963_CR90","doi-asserted-by":"crossref","unstructured":"O\u2019Hare M, Miller WP, Arevalo-Alquichire S, Amarnani D, Apryani E, Perez-Corredor P, An mRNA-encoded dominant-negative inhibitor of transcription factor RUNX1 suppresses vitreoretinal disease in experimental models. Sci Transl Med. 2024;16(775):eadh0994.","DOI":"10.1126\/scitranslmed.adh0994"},{"key":"3963_CR91","doi-asserted-by":"publisher","first-page":"20554","DOI":"10.1038\/s41598-020-77254-0","volume":"10","author":"S Delgado-Tirado","year":"2020","unstructured":"Delgado-Tirado S, Amarnani D, Zhao G, Rossin EJ, Eliott D, Miller JB (2020) Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy. Sci Rep 10:20554","journal-title":"Sci Rep"},{"key":"3963_CR92","doi-asserted-by":"publisher","first-page":"108622","DOI":"10.1016\/j.exer.2021.108622","volume":"208","author":"N Daftarian","year":"2021","unstructured":"Daftarian N, Baigy O, Suri F, Kanavi MR, Balagholi S, Afsar Aski S (2021) Intravitreal connective tissue growth factor neutralizing antibody or bevacizumab alone or in combination for prevention of proliferative vitreoretinopathy in an experimental model. Exp Eye Res 208:108622","journal-title":"Exp Eye Res"},{"issue":"5","key":"3963_CR93","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3892\/mmr.2021.12028","volume":"23","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chang T, Wu T, Ye W, Wang Y, Dou G (2021) Connective tissue growth factor promotes retinal pigment epithelium mesenchymal transition via the PI3K\/AKT signaling pathway. Mol Med Rep 23(5):389","journal-title":"Mol Med Rep"},{"issue":"10","key":"3963_CR94","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.3390\/jcm11102716","volume":"11","author":"GKG Nair","year":"2022","unstructured":"Nair GKG, Pollalis D, Wren JD, Georgescu C, Sjoelund V, Lee SY (2022) Proteomic Insight into the role of exosomes in proliferative vitreoretinopathy development. J Clin Med 11(10):2716","journal-title":"J Clin Med"},{"key":"3963_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.643680","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Mugisha A, Fransisca S, Liu Q, Xie P, Hu Z (2021) Emerging role of exosomes in retinal diseases. Front Cell Dev Biol 9:643680","journal-title":"Front Cell Dev Biol"},{"key":"3963_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.107973","volume":"193","author":"W Zhang","year":"2020","unstructured":"Zhang W, Jiang H, Kong Y (2020) Exosomes derived from platelet-rich plasma activate YAP and promote the fibrogenic activity of M\u00fcller cells via the PI3K\/Akt pathway. Exp Eye Res 193:107973","journal-title":"Exp Eye Res"},{"key":"3963_CR97","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. Users\u2019 guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA. 1995;274(22):1800\u20134.","DOI":"10.1001\/jama.1995.03530220066035"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-03963-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-03963-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-03963-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:02:24Z","timestamp":1769839344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-03963-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3963"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-03963-6","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conmpeting interest"}},{"value":"This review relies solely on analysis of existing literature and does not include new experimental research; therefore, ethical approval is not required. Consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This review relies solely on analysis of existing literature and does not include new experimental research; therefore, participant consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"94"}}